Telogen Effluvium Clinical Trial
Official title:
Controlled, Randomized, Double Blind Study, for the Evaluation of Tolerance and Trichological Efficacy of a Food Supplement: Bioscalin® New Formulation Versus Reference Formulation Currently on the Market and Placebo
Verified date | September 2017 |
Source | Derming SRL |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Controlled, randomized, double blind study, for the evaluation of tolerance and trichological efficacy of a food supplement: Bioscalin® new formulation versus reference formulation currently on the market and placebo
Status | Completed |
Enrollment | 51 |
Est. completion date | March 31, 2017 |
Est. primary completion date | March 31, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - both sexes; - age range 18-60 years old; - with telogen effluvium and a percentage of anagen ratio at inclusion < 75%; - no-smokers; - accepting to follow the instruction received by the investigator; - disposable and able to return to the study centre at the established times; - accepting to not change their habits regarding food, physical activity, hair and scalp cleansing; - accepting to not receive any drugs/cosmetics treatment able to interfere with the study results; - no participation in a similar study actually or during the previous 6 months; - accepting to sign the Informed consent form. Exclusion Criteria: - Pregnancy (for female subjects); - lactation (for female subjects); - subjects not in menopause who does not use adequate contraceptive precautions in order to avoid pregnancies during the study; - subjects not in menopause who do not accept to perform the pregnancy test during the basal visit, after 2 (T2) and 3 (T3) month-treatment; - change in the normal habits regarding food, physical activity, physical activity, hair and scalp cleansing during the month preceding the test; - sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit). The product contains gluten (aroma of grain), then all subjects with celiac disease or gluten intolerance should be excluded. - subjects whose insufficient adhesion to the study protocol is foreseeable; - participation in a similar study actually or during the previous 6 months. - presence of cutaneous disease on the tested area, as lesions, scars, malformations; - clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.). - Diabetes - endocrine disease - hepatic disorder - renal disorder - cardiac disorder - pulmonary disease - cancer - neurological or psychological disease - inflammatory/immunosuppressive disease - drug allergy - anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago); - assumption of drugs able to influence the test results in the investigator opinion. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Derming SRL |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline of the percentage of hair in anagen phase | Percentage of hair in anagen phase (anagen hair grow > 0,3 mm/die ) was calculate by TrichoScan software on the microscopic images (with 20X magnification) captured with FotoFinderDermoscope. | Basal visit (T0),1 month (T1), 2 months (T2), 3 months (T3), 4 months (T4). | |
Primary | Change from baseline of the hair density | Hair density (hair number/cm2) was calculate by TrichoScan software on the microscopic images (with 20X magnification) captured with FotoFinderDermoscope. | Basal visit (T0),1 month (T1), 2 months (T2), 3 months (T3), 4 months (T4). | |
Primary | Change from baseline of the percentage of vellus hair | Percentage of vellus hair (vellus hair has a diameter <0.04 mm)was calculate by TrichoScan software on the microscopic images (with 20X magnification) captured with FotoFinderDermoscope. | Basal visit (T0),1 month (T1), 2 months (T2), 3 months (T3), 4 months (T4). | |
Secondary | Hair parting test | Evaluation of hair thickening | Basal visit (T0), after 1 (T1), 2 (T2) and 3 (T3) month-treatment and a follow-up visit 1 month after the last food supplement assumption (T4 months). | |
Secondary | Videodermatoscopy | Evaluation to visualize any morphological alteration/variation of the hair often imperceptible to the naked eye | Basal visit (T0), after 1 (T1), 2 (T2) and 3 (T3) month-treatment and a follow-up visit 1 month after the last food supplement assumption (T4 months). | |
Secondary | Pull test | Evaluation of tensile strength of the hair | Basal visit (T0), after 1 (T1), 2 (T2) and 3 (T3) month-treatment and a follow-up visit 1 month after the last food supplement assumption (T4 months). | |
Secondary | Sebometry | Measurement of surface lipid level | Basal visit (T0), after 1 (T1), 2 (T2) and 3 (T3) month-treatment and a follow-up visit 1 month after the last food supplement assumption (T4 months). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04237402 -
Demonstration of the Presence of a Carbonyl Stress in the Hair Follicles of Postpartum Women
|
N/A | |
Terminated |
NCT02548689 -
PAI-1 Expression in Non-scarring Hair Loss
|
||
Recruiting |
NCT04834102 -
COVID-19 Induced Telogen Effluvium
|
||
Not yet recruiting |
NCT04880889 -
BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.
|
Phase 3 | |
Completed |
NCT04652232 -
Efficacy Study of Cosmetic Product Against Telogen Effluvium on Women
|
N/A | |
Completed |
NCT04450602 -
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
|
N/A | |
Completed |
NCT04450589 -
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
|
N/A |